Compare ARAY & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARAY | MGNX |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.5M | 115.8M |
| IPO Year | 2007 | 2013 |
| Metric | ARAY | MGNX |
|---|---|---|
| Price | $0.60 | $1.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 5 |
| Target Price | ★ $3.50 | $3.20 |
| AVG Volume (30 Days) | 782.5K | ★ 946.3K |
| Earning Date | 02-04-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $436,969,000.00 | $127,626,000.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $4.08 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.99 |
| 52 Week High | $2.95 | $3.02 |
| Indicator | ARAY | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 22.22 | 49.06 |
| Support Level | $0.56 | $1.66 |
| Resistance Level | $0.83 | $1.97 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 17.06 | 29.58 |
Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, treatment solutions which set the standard of radiation therapy care with the objective of helping patients live lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.